

Publikationen der Universitätsklinik und Poliklinik für Innere Medizin IV 2016-2019

1. Aapro M, Hesketh PJ, Jordan K, Gralla RJ, Rossi G, Rizzi G, Palmas M (2016) Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program. *ONCOLOGIST*, 21: 494-502
2. Alsdorf WH, Schmitz M, Schieferdecker A, Dierlamm J, Bokemeyer C, Binder M (2016) Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature. *JOURNAL OF ONCOLOGY PHARMACY PRACTICE*, 22: 523-7
3. Bacher U, Binder M (2016) Modifying therapy in patients with advanced Hodgkin's lymphoma by integrating early metabolic response by interim PET-CT. *Annals of Translational Medicine*, 4: S19
4. Bäumer N, Appel N, Terheyden L, Buchholz F, Rossig C, Müller-Tidow C, Berdel WE, Bäumer S (2016) Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown. *Nature Protocols*, 11: 22-36
5. Braig F, Voigtlaender M, Schieferdecker A, Busch CJ, Laban S, Grob T, Kriegs M, Knecht R, Bokemeyer C, Binder M (2016) Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. *ONCOTARGET*, 7: 42988-42995
6. Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W (2016) Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia. *LEUKEMIA*, 30: 1781-4
7. Bzymek R, Horsthemke M, Isfort K, Mohr S, Tjaden K, Müller-Tidow C, Thomann M, Schwerdtle T, Bähler M, Schwab A, Hanley PJ (2016) Real-time two- and three-dimensional imaging of monocyte motility and navigation on planar surfaces and in collagen matrices: roles of Rho. *Scientific Reports*, 6: 25016
8. Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Goparaju R, Schwarzer A, Görlich K, Schottmann R, Struys EA, Jansen EE, Rohde C, Müller-Tidow C, Geffers R, Göhring G, Ganser A, Thol F, Heuser M (2016) Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. *LEUKEMIA*, 30: 1708-15
9. Etrych T, Lucas H, Janoušková O, Chytil P, Mueller T, Mäder K (2016) Fluorescence optical imaging in anticancer drug delivery. *JOURNAL OF CONTROLLED RELEASE*, 226: 168-81
10. Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (IELSG) (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. *Lancet Haematology*, 3: e217-27

11. Fichtner M, Spies E, Seismann H, Riecken K, Engels N, Gösch B, Dierlamm J, Gerull H, Nollau P, Klapper W, Dreyling M, Binder M, Trepel M (2016) Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma. *HAEMATOLOGICA*, 101: e378-81
12. Grabner A, Kentrup D, Pawelski H, Mühlmeister M, Biermann C, Edemir B, Heitplatz B, Van Marck V, Bettinger T, Pavenstädt H, Schlatter E, Stypmann J, Tiemann K, Reuter S (2016) Renal Contrast-Enhanced Sonography Findings in a Model of Acute Cellular Allograft Rejection. *AMERICAN JOURNAL OF TRANSPLANTATION*, 16: 1612-9
13. Harrach S, Schmidt-Lauber C, Pap T, Pavenstädt H, Schlatter E, Schmidt E, Berdel WE, Schulze U, Edemir B, Jeromin S, Haferlach T, Ciarimboli G, Bertrand J (2016) MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients. *Blood Cancer Journal*, 6: e470
14. Heinrich AK, Lucas H, Schindler L, Chytil P, Etrych T, Mäder K, Mueller T (2016) Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance. *MOLECULAR CANCER THERAPEUTICS*, 15: 998-1007
15. Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, Danso MA, Jordan K, Somerfield MR, Kris MG, American Society of Clinical Oncology (2016) Antiemetics: American Society of Clinical Oncology Focused Guideline Update. *JOURNAL OF CLINICAL ONCOLOGY*, 34: 381-6
16. Hesketh PJ, Schnadig ID, Schwartzberg LS, Modiano MR, Jordan K, Arora S, Powers D, Aapro M (2016) Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. *CANCER*, 122: 2418-25
17. Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, Wolf HH, Hirt C, Stilgenbauer S, Binder M, Hau P, Edinger M, Frickhofen N, Bentz M, Möhle R, Röth A, Pfreundschuh M, von Baumgarten L, Deckert M, Hader C, Fricker H, Valk E, Schorb E, Fritsch K, Finke J (2016) High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. *Lancet Haematology*, 3: e388-97
18. Jakobs A, Uttarkar S, Schomburg C, Steinmann S, Coulibaly A, Schlenke P, Berdel WE, Müller-Tidow C, Schmidt TJ, Klempnauer KH (2016) An isoform-specific C/EBP β inhibitor targets acute myeloid leukemia cells. *LEUKEMIA*, 30: 1612-5
19. Jordan B, Jahn F, Beckmann J, Unverzagt S, Müller-Tidow C, Jordan K (2016) Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review. *ONCOLOGY*, 90: 299-306
20. Jordan B, Kellner J, Jordan K, Bähre M, Behrmann C, Zierz S (2016) Thymic pathologies in myasthenia gravis: a preoperative assessment of CAT scan and nuclear based imaging. *JOURNAL OF NEUROLOGY*, 263: 641-8
21. Jordan K, Gralla R, Rizzi G, Kashef K (2016) Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. *SUPPORTIVE CARE IN CANCER*, 24: 4617-25
22. Jordan K, Warr DG, Hinke A, Sun L, Hesketh PJ (2016) Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis. *SUPPORTIVE CARE IN CANCER*, 24: 1941-54
23. Jordan K, Luetkens T, Gog C, Killing B, Arnold D, Hinke A, Stahl M, Freier W, Rüssel J, Atanackovic D, Hegewisch-Becker S (2016) Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108. *EUROPEAN JOURNAL OF CANCER*, 63: 127-34

24. Kriegs M, Kasten-Pisula U, Riepen B, Hoffer K, Struve N, Myllynen L, Braig F, Binder M, Rieckmann T, Grénman R, Petersen C, Dikomey E, Rothkamm K (2016) Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests. *ONCOTARGET*, 7: 45122-45133
25. Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T (2016) Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. *LEUKEMIA*, 30: 1230-6
26. Lavallée VP, Kros J, Lemieux S, Boucher G, Gendron P, Pabst C, Boivin I, Marinier A, Guidos CJ, Meloche S, Hébert J, Sauvageau G (2016) Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors. *BLOOD*, 127: 3054-61
27. Leithold C, Jordan K, Jahn F, Behlendorf T, Schaffrath J, Müller-Tidow C, Rüssel J (2016) Diagnostic work-up for the detection of malnutrition in hospitalized cancer patients. *J Community Support Oncol*, 14: 155-61
28. Liebscher G, Vanchangiri K, Mueller T, Feige K, Cavalleri JMV, Paschke R (2016) In vitro anticancer activity of Betulinic acid and derivatives thereof on equine melanoma cell lines from grey horses and in vivo safety assessment of the compound NVX-207 in two horses. *CHEMICO-BIOLOGICAL INTERACTIONS*, 246: 20-9
29. Lofruchte N, Gallitz I, Traeger L, Bäumer N, Schulze I, Kuhlmann T, Müller-Tidow C, Steinbicker AU (2016) Intravenous Iron Carboxymaltose as a Potential Therapeutic in Anemia of Inflammation. *PLoS One*, 11: e0158599
30. Lomkova EA, Chytil P, Janoušková O, Mueller T, Lucas H, Filippov SK, Trhlíková O, Aleshunin PA, Skorik YA, Ulbrich K, Etrych T (2016) Biodegradable Micellar HPMA-Based Polymer-Drug Conjugates with Betulinic Acid for Passive Tumor Targeting. *BIOMACROMOLECULES*, 17: 3493-3507
31. Mahal K, Biersack B, Schrufer S, Resch M, Ficner R, Schobert R, Mueller T (2016) Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors. *EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY*, 118: 9-20
32. Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink AM, Eichhorst B, Kreuzer KA, Fischer N, Tausch E, Stilgenbauer S, Böttcher S, Döhner H, Kneba M, Dreyling M, Binder M, Hallek M, Wendtner CM, Bergmann M, Fischer K, German CLL Study Group (2016) Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. *EUROPEAN JOURNAL OF HAEMATOLOGY*, 97: 253-60
33. Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience PC, Ruessel J, Hegewisch-Becker S, Wilke H, Al-Batran SE, Rafiyan MR, Weißinger F, Schmoll HJ, Kullmann F, von Weikersthal LF, Siveke JT, Weusmann J, Kanzler S, Schimanski CC, Otte M, Schollenberger L, Koenig J, Galle PR (2016) Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. *BMC CANCER*, 16: 699
34. Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppene R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M,

- Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U, Study Alliance Leukemia Group (2016) Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia. *LEUKEMIA*, 30: 555-61
35. Pabst C, Bergeron A, Lavallée VP, Yeh J, Gendron P, Norddahl GL, Krosil J, Boivin I, Deneault E, Simard J, Imren S, Boucher G, Eppert K, Herold T, Bohlander SK, Humphries K, Lemieux S, Hébert J, Sauvageau G, Barabé F (2016) GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. *BLOOD*, 127: 2018-27
36. Pohlen M, Groth C, Sauer T, Görlich D, Mesters R, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Berdel WE, Stelljes M (2016) Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (≥ 60 years). *BONE MARROW TRANSPLANTATION*, 51: 1441-1448
37. Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch JH, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Krug U, Stelljes M, Karch H, Peters G, Gerth HU, Görlich D, Berdel WE (2016) Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center. *HAEMATOLOGICA*, 101: 1208-1215
38. Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer KA, Lebiecz P, Görlich D, Gerth HU, Rohde C, Kessler T, Müller-Tidow C, Stelljes M, Büchner T, Schlimok G, Hallek M, Waltenberger J, Hiddemann W, Berdel WE, Heilmeyer B, Krug U (2016) Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. *PLoS One*, 11: e0160871
39. Pola R, Heinrich AK, Mueller T, Kostka L, Mäder K, Pechar M, Etrych T (2016) Passive Tumor Targeting of Polymer Therapeutics: In Vivo Imaging of Both the Polymer Carrier and the Enzymatically Cleavable Drug Model. *MACROMOLECULAR BIOSCIENCE*, 16: 1577-1582
40. Potratz J, Tillmanns A, Berning P, Korsching E, Schaefer C, Lechtape B, Schleithoff C, Unland R, Schäfer KL, Müller-Tidow C, Jürgens H, Dirksen U (2016) Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease. *Molecular Oncology*, 10: 677-92
41. Riemke P, Czeh M, Fischer J, Walter C, Ghani S, Zepper M, Agelopoulos K, Lettermann S, Gebhardt ML, Mah N, Weilemann A, Grau M, Gröning V, Haferlach T, Lenze D, Delwel R, Prinz M, Andrade-Navarro MA, Lenz G, Dugas M, Müller-Tidow C, Rosenbauer F (2016) Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors. *EMBO JOURNAL*, 35: 2399-2416
42. Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. *ANNALS OF ONCOLOGY*, 27: v119-v133
43. Schelhaas S, Held A, Bäumer N, Viel T, Hermann S, Müller-Tidow C, Jacobs AH (2016) Preclinical Evidence That 3'-Deoxy-3'-[18F]Fluorothymidine PET Can Visualize Recovery of Hematopoiesis after Gemcitabine Chemotherapy. *CANCER RESEARCH*, 76: 7089-7095
44. Schemionek M, Herrmann O, Reher MM, Chatain N, Schubert C, Costa IG, Hänzelmann S, Gusmao EG, Kintsler S, Braunschweig T, Hamilton A, Helgason GV, Copland M, Schwab A, Müller-Tidow C, Li S, Holyoake TL, Brümmendorf TH,

- Koschmieder S (2016) Mtss1 is a critical epigenetically regulated tumor suppressor in CML. *LEUKEMIA*, 30: 823-32
45. Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Mieth S, Hust M, Braig F, Voigt M, von Pein UM, Koch-Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M (2016) A transplant "immunome" screening platform defines a targetable epitope fingerprint of multiple myeloma. *BLOOD*, 127: 3202-14
 46. Schliemann C, Gerss J, Wiebe S, Mikesch JH, Knoblauch N, Sauer T, Angenendt L, Kewitz T, Urban M, Butterfass-Bahloul T, Edemir S, Vehring K, Müller-Tidow C, Berdel WE, Krug U (2016) A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia. *PLoS One*, 11: e0164499
 47. Schliffke S, Akyüz N, Ford CT, Mährle T, Thenhausen T, Krohn-Grimberghe A, Knop S, Bokemeyer C, Binder M (2016) Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia. *LEUKEMIA*, 30: 2232-2234
 48. Schmidt H, Merkel D, Koehler M, Flechtner HH, Sigle J, Klinge B, Jordan K, Vordermark D, Landenberger M, Jahn P (2016) PRO-ONKO-selection of patient-reported outcome assessments for the clinical use in cancer patients-a mixed-method multicenter cross-sectional exploratory study. *SUPPORTIVE CARE IN CANCER*, 24: 2503-12
 49. Schmitt F, Donnelly K, Muenzner JK, Rehm T, Novohradsky V, Brabec V, Kasparikova J, Albrecht M, Schobert R, Mueller T (2016) Effects of histidin-2-ylidene vs. imidazol-2-ylidene ligands on the anticancer and antivascular activity of complexes of ruthenium, iridium, platinum, and gold. *JOURNAL OF INORGANIC BIOCHEMISTRY*, 163: 221-228
 50. Schulze Blasum B, Schröter R, Neugebauer U, Hofschröer V, Pavenstädt H, Ciarimboli G, Schlatter E, Edemir B (2016) The kidney-specific expression of genes can be modulated by the extracellular osmolality. *FASEB JOURNAL*, 30: 3588-3597
 51. Schulze I, Rohde C, Scheller-Wendorff M, Bäumer N, Krause A, Herbst F, Riemke P, Hebestreit K, Tschanter P, Lin Q, Linhart H, Godley LA, Glimm H, Dugas M, Wagner W, Berdel WE, Rosenbauer F, Müller-Tidow C (2016) Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. *BLOOD*, 127: 1575-86
 52. Shumilov E, Wulf G, Ströbel P, Hasenkamp J, Hellige N, Bleckmann A, Haase D, Braulke F, Jung W, Schanz J, Binder M, Trümper L, Bacher U (2016) Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib. *LEUKEMIA & LYMPHOMA*, 57: 2476-80
 53. Stucke-Ring J, Ronnacker J, Brand C, Höltke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wünsch B, Müller-Tidow C, Mesters RM, Schwöppe C, Berdel WE (2016) Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. *ONCOTARGET*, 7: 82458-82472
 54. Sun H, Lin DC, Guo X, Kharabi Masouleh B, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koefler HP (2016) Inhibition of IRE1 α -driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. *ONCOTARGET*, 7: 18736-49
 55. Uttarkar S, Dassé E, Coulibaly A, Steinmann S, Jakobs A, Schomburg C, Trentmann A, Jose J, Schlenke P, Berdel WE, Schmidt TJ, Müller-Tidow C, Frampton J, Klempnauer KH (2016) Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction. *BLOOD*, 127: 1173-82

56. Uttarkar S, Piontek T, Dukare S, Schomburg C, Schlenke P, Berdel WE, Müller-Tidow C, Schmidt TJ, Klempnauer KH (2016) Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells. *MOLECULAR CANCER THERAPEUTICS*, 15: 2905-2915
57. Varghese J, Holz C, Neuhaus P, Bernardi M, Boehm A, Ganser A, Gore S, Heaney M, Hochhaus A, Hofmann WK, Krug U, Müller-Tidow C, Smith A, Weltermann A, de Witte T, Hehlmann R, Dugas M (2016) Key Data Elements in Myeloid Leukemia. *Stud Health Technol Inform*, 228: 282-6
58. Vitavska O, Edemir B, Wieczorek H (2016) Putative role of the H(+)/sucrose symporter SLC45A3 as an osmolyte transporter in the kidney. *PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY*, 468: 1353-62
59. von Lilienfeld-Toal M, Berger A, Christopeit M, Hentrich M, Heussel CP, Kalkreuth J, Klein M, Kochanek M, Penack O, Hauf E, Rieger C, Silling G, Vehreschild M, Weber T, Wolf HH, Lehnert N, Schalk E, Mayer K (2016) Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. *EUROPEAN JOURNAL OF CANCER*, 67: 200-212
60. Wass M, Hitz F, Schaffrath J, Müller-Tidow C, Müller LP (2016) Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia. *PLoS One*, 11: e0164587
61. Weber T, Niestadtkötter J, Wienke A, Müller-Tidow C, Müller LP (2016) Enteric-coated mycophenolate sodium containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT. *EUROPEAN JOURNAL OF HAEMATOLOGY*, 97: 232-8
62. Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Vallejos W, Liang LW, Noga SJ, Rapoport BL (2016) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. *ANNALS OF ONCOLOGY*, 27: 172-8
63. Widder M, Lützkendorf J, Caysa H, Unverzagt S, Wickenhauser C, Benndorf RA, Schmoll HJ, Müller-Tidow C, Müller T, Müller LP (2016) Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a β 1-integrin-dependent mechanism. *INTERNATIONAL JOURNAL OF CANCER*, 138: 964-75
64. Wolf HH, Kornhuber ME, Weis J, Posa A (2016) Dysautonomic polyneuropathy as a variant of chronic inflammatory "demyelinating" polyneuropathy? *CLINICAL AUTONOMIC RESEARCH*, 26: 303-5
65. Aapro M, Jordan K, Gralla RJ, Rizzi G, Rossi G, Palmas M, Alyasova AV, Lisyanskaya AS, Bošnjak SM, Hesketh PJ (2017) Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients. *Journal of Geriatric Oncology*, 8: 56-63
66. Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford CT, Asemussen AM, Thiele B, Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Binder M (2017) T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. *INTERNATIONAL JOURNAL OF CANCER*, 140: 2535-2544
67. Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippel P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L (2017) Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A

Retrospective Multinational Study. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 18: XY

68. Bähr I, Goritz V, Doberstein H, Hiller GGR, Rosenstock P, Jahn J, Pörtner O, Berreis T, Mueller T, Spielmann J, Kielstein H (2017) Diet-Induced Obesity Is Associated with an Impaired NK Cell Function and an Increased Colon Cancer Incidence. *J Nutr Metab*, 2017: 4297025
69. Braig F, Brandt A, Goebeler M, Tony HP, Kurze AK, Nollau P, Bumm T, Böttcher S, Bargou RC, Binder M (2017) Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. *BLOOD*, 129: 100-104
70. Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Märkl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M (2017) Polymorphism. *CANCER RESEARCH*, 77: 1188-1199
71. Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C (2017) Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus. *BLOOD*, 129: 319-323
72. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderkov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (IELSG) (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. *Lancet Haematology*, 4: e510-e523
73. Fichtner M, Dreyling M, Binder M, Trepel M (2017) The role of B cell antigen receptors in mantle cell lymphoma. *Journal of Hematology & Oncology*, 10: 164
74. Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Heß G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Röth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G (2017) High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). *LEUKEMIA*, 31: 846-852
75. Fumey W, Koenigsdorf J, Kunick V, Menzel S, Schütze K, Unger M, Schriewer L, Haag F, Adam G, Oberle A, Binder M, Fliegert R, Guse A, Zhao YJ, Cheung Lee H, Malavasi F, Goldbaum F, van Hegelsom R, Stortelers C, Bannas P, Koch-Nolte F (2017) tumors in mouse models in vivo. *Scientific Reports*, 7: 14289
76. Göllner S, Müller-Tidow C (2017) Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia. *Mol Cell Oncol*, 4: e1291396
77. Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehniger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C (2017) Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. *NATURE MEDICINE*, 23: 69-78

78. Harrach S, Edemir B, Schmidt-Lauber C, Pap T, Bertrand J, Ciarimboli G (2017) Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts. *Scientific Reports*, 7: 1258
79. Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T (2017) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. *LEUKEMIA*, 31: 775
80. Hermann B, Lehnert N, Brodhun M, Boden K, Hochhaus A, Kochanek M, Meckel K, Mayer K, Rachow T, Rieger C, Schalk E, Weber T, Schmeier-Jürchott A, Schlattmann P, Teschner D, von Lilienfeld-Toal M (2017) Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO). *EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES*, 36: 565-573
81. Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Warr D, Hesketh PJ (2017) 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. *SUPPORTIVE CARE IN CANCER*, 25: 271-275
82. Jordan K, Feyer P, Höller U, Link H, Wörmann B, Jahn F (2017) Supportive Treatments for Patients with Cancer. *Deutsches Arzteblatt International*, 114: 481-487
83. Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G (2017) High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. *LEUKEMIA*, 31: 2623-2629
84. Koehler P, Hamprecht A, Bader O, Bekeredjian-Ding I, Buchheidt D, Doelken G, Elias J, Haase G, Hahn-Ast C, Karthaus M, Kekulé A, Keller P, Kiehl M, Krause SW, Krämer C, Neumann S, Rohde H, La Rosée P, Ruhnke M, Schafhausen P, Schalk E, Schulz K, Schwartz S, Silling G, Staib P, Ullmann A, Vergoulidou M, Weber T, Cornely OA, Vehreschild MJGT (2017) Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. *INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS*, 49: 218-223
85. Körbelin J, Hunger A, Alawi M, Sieber T, Binder M, Trepel M (2017) Optimization of design and production strategies for novel adeno-associated viral display peptide libraries. *GENE THERAPY*, 24: 470-481
86. Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T (2017) Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). *JOURNAL OF CLINICAL ONCOLOGY*, 35: 2157-2164
87. Ligeti K, Müller L, Müller-Tidow C, Weber T (2017) Risk factors, diagnosis, and management of posttransplant lymphoproliferative disorder: improving patient outcomes with a multidisciplinary treatment approach. *DOVE PRESS*, 2017: 1-14
88. Lützkendorf J, Wieduwild E, Nerger K, Lambrecht N, Schmoll HJ, Müller-Tidow C, Müller LP (2017) Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest. *PLoS One*, 12: e0169921

89. Macherey S, Monsef I, Jahn F, Jordan K, Yuen KK, Heidenreich A, Skoetz N (2017) Bisphosphonates for advanced prostate cancer. *Cochrane Database of Systematic Reviews*, 12: CD006250
90. Mohr S, Doebele C, Comoglio F, Berg T, Beck J, Bohnenberger H, Alexe G, Corso J, Ströbel P, Wachter A, Beissbarth T, Schnütgen F, Cremer A, Haetscher N, Göllner S, Rouhi A, Palmqvist L, Rieger MA, Schroeder T, Bönig H, Müller-Tidow C, Kuchenbauer F, Schütz E, Green AR, Urlaub H, Stegmaier K, Humphries RK, Serve H, Oellerich T (2017) Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. *CANCER CELL*, 31: 549-562.e11
91. Mueller T, Pfankuchen DB, Wantoch von Rekowski K, Schlesinger M, Reipsch F, Bendas G (2017) The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models. *MOLECULES*, 22: E728
92. Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, Binder M (2017) Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. *HAEMATOLOGICA*, 102: e368-e370
93. Oberle A, Brandt A, Voigtlaender M, Thiele B, Radloff J, Schulkorf A, Alawi M, Akyüz N, März M, Ford CT, Krohn-Grimberghe A, Binder M (2017) Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. *HAEMATOLOGICA*, 102: 1105-1111
94. Olver I, Ruhlmann CH, Jahn F, Schwartzberg L, Rapoport B, Rittenberg CN, Clark-Snow R (2017) 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. *SUPPORTIVE CARE IN CANCER*, 25: 297-301
95. Roila F, Warr D, Hesketh PJ, Gralla R, Herrstedt J, Jordan K, Aapro M, Ballatori E, Rapoport B (2017) 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy. *SUPPORTIVE CARE IN CANCER*, 25: 289-294
96. Rossi A, Voigtlaender M, Janjetovic S, Thiele B, Alawi M, März M, Brandt A, Hansen T, Radloff J, Schön G, Hegenbart U, Schönland S, Langer C, Bokemeyer C, Binder M (2017) Mutational landscape reflects the biological continuum of plasma cell dyscrasias. *Blood Cancer Journal*, 7: e537
97. Ruhlmann CH, Jahn F, Jordan K, Dennis K, Maranzano E, Molassiotis A, Roila F, Feyer P (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting. *SUPPORTIVE CARE IN CANCER*, 25: 309-316
98. Schaffrath J, Schmoll HJ, Voigt W, Müller LP, Müller-Tidow C, Mueller T (2017) Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. *PLoS One*, 12: e0178930
99. Schmidt H, Boese S, Lampe K, Jordan K, Fiedler E, Müller-Werdan U, Wienke A, Vordermark D (2017) Trans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concept for geriatric oncology patients (PIVOG). *Journal of Geriatric Oncology*, 8: 262-270
100. Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H (2017) Azacitidine improves clinical outcomes in older patients with acute

- myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. *BMC CANCER*, 17: 852
101. Simmermacher S, Vordermark D, Kegel T, Strauss C (2017) [Malignization of vestibular schwannoma 13 years after radiation therapy]. *HNO*, 65: 766-770
 102. Simmermacher S, Vordermark D, Kegel T, Strauss C (2017) Malignization of a vestibular schwannoma 13 years after radiation therapy. *HNO*, 65: 153-157
 103. Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP (2017) A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. *LEUKEMIA*, 31: 896-902
 104. Thoennissen GB, Görlich D, Bacher U, Aufenberg T, Hüsken AC, Hansmeier AA, Evers G, Mikesch JH, Fritz F, Bokemeyer C, Müller-Tidow C, Stelljes M, Mesters RM, Krug U, Kropff MH, Thoennissen NH, Berdel WE (2017) Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. *ACTA HAEMATOLOGICA*, 137: 163-172
 105. Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Hüttelmaier S, Müller-Tidow C (2017) AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. *NATURE CELL BIOLOGY*, 19: 844-855
 106. Bera TK, Abe Y, Ise T, Oberle A, Gallardo D, Liu XF, Nagata S, Binder M, Pastan I (2018) Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients. *LEUKEMIA*, 32: 569-572
 107. Betten R, Scharner B, Probst S, Edemir B, Wolff NA, Langelueddecke C, Lee WK, Thévenod F (2018) Tonicity inversely modulates lipocalin-2 (Lcn2/24p3/NGAL) receptor (SLC22A17) and Lcn2 expression via Wnt/ β -catenin signaling in renal inner medullary collecting duct cells: implications for cell fate and bacterial infection. *Cell Communication and Signaling*, 16: 74
 108. Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M (2018) European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. *HAEMATOLOGICA*, 103: 1772-1784
 109. Döhner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, Del Castillo TB, Al-Ali HK, Santini V, Vyas P, Beach CL, MacBeth KJ, Skikne BS, Songer S, Tu N, Bullinger L, Dombret H (2018) Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. *LEUKEMIA*, 32: 2546-2557
 110. Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, Nagler A, Scheid C, Cornelissen J, Niederwieser D, Müller L, Vandenberghe E, Scortechini I, Schoemans H, Andersen NS, Finke J, Russo D, Ljungman P, Passweg J, van Gelder M, Durakovic N, Labussiere-Wallet H, Berg T, Wulf G, Bethge W, Bunjes D, Stilgenbauer S, Canepari ME, Schaap M, Fox CP, Kröger N, Montoto S, Schetelig J (2018) Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. *BONE MARROW TRANSPLANTATION*, epub: epub

111. Edemir B (2018) Considering hypertonicity in the interpretation and analysis of cell type-specific gene expression pattern in the collecting duct. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 115: E349-E350
112. Heidel FH, Al-Ali HK, Hirt C, Kämpfe D, Jentsch-Ullrich K, Junghanss C, Nowak R, Schwarzer A, Spohn C, Vucinic V, Hochhaus A, Lange T, Working Party Myeloproliferative Neoplasms of the East German Study Group Hematology/Oncology (OSHO) (2018) Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. LEUKEMIA, 32: 2085-2087
113. Jordan K, Blättermann L, Hinke A, Müller-Tidow C, Jahn F (2018) Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis. SUPPORTIVE CARE IN CANCER, 26: 21-32
114. Kurze C, Le Conte Y, Kryger P, Lewkowski O, Müller T, Moritz RFA (2018) Infection dynamics of Nosema ceranae in honey bee midgut and host cell apoptosis. JOURNAL OF INVERTEBRATE PATHOLOGY, 154: 1-4
115. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. NATURE MEDICINE, 24: 282-291
116. Mohme M, Schliffke S, Maire CL, Rüniger A, Glau L, Mende KC, Matschke J, Gehbauer C, Akyüz N, Zapf S, Holz M, Schaper M, Martens T, Schmidt NO, Peine S, Westphal M, Binder M, Tolosa E, Lamszus K (2018) Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes. CLINICAL CANCER RESEARCH, 24: 4187-4200
117. Mueller T, Hantsch C, Volkmer I, Staeger MS (2018) Differentiation-Dependent Regulation of Human Endogenous Retrovirus K Sequences and Neighboring Genes in Germ Cell Tumor Cells. Frontiers in Microbiology, 9: 1253
118. Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Bühler C, Marcantonio DD, Martinez E, Göllner S, Wickenhauser C, Müller-Tidow C, Lutz C, Bullinger L, Milsom MD, Sykes SM, Fröhling S, Scholl C (2018) RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. LEUKEMIA, 32: 2189-2202

119. Ruhnke M, Behre G, Buchheidt D, Christopeit M, Hamprecht A, Heinz W, Heussel CP, Horger M, Kurzai O, Karthaus M, Löffler J, Maschmeyer G, Penack O, Rieger C, Rickerts V, Ritter J, Schmidt-Hieber M, Schuelper N, Schwartz S, Ullmann A, Vehreschild JJ, von Lilienfeld-Toal M, Weber T, Wolf HH (2018) Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). *MYCOSES*, 61: 796-813
120. Schliffke S, Buhs S, Bolz S, Gerull H, von Wenserski L, Riecken K, Fehse B, Nollau P, Binder M (2018) The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia. *BLOOD*, 131: 1755-1758
121. Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M (2018) Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. *ONCOIMMUNOLOGY*, 7: e1417720
122. Schmitt F, Gold M, Rothemund M, Andronache I, Biersack B, Schobert R, Mueller T (2018) New naphthopyran analogues of LY290181 as potential tumor vascular-disrupting agents. *EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY*, 163: 160-168
123. Terziev D, Hutter B, Klink B, Stenzinger A, Stögbauer F, Glimm H, Fröhling S, Wickenhauser C, Jordan K, Hurtz HJ, Müller LP, Rüssel J, Weber T (2018) Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma. *EUROPEAN JOURNAL OF HAEMATOLOGY*, 101: 115-118
124. van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, Kröger N, CLL subcommittee, Chronic Malignancies Working Party of the EBMT (2018) Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. *BONE MARROW TRANSPLANTATION*, 53: 255-263
125. Wass M, Bauer M, Pfannes R, Lorenz K, Odparlik A, Müller LP, Wickenhauser C (2018) Chronic active Epstein-Barr virus infection of T-cell type, systemic form in an African migrant: case report and review of the literature on diagnostics standards and therapeutic options. *BMC CANCER*, 18: 941
126. Weber T, Ljungman P (2018) Stringent vaccination of cancer patients: is it that important? *ANNALS OF ONCOLOGY*, 29: 1348-1349
127. Weiss VM, Lucas H, Mueller T, Chytil P, Etrych T, Naolou T, Kressler J, Mäder K (2018) Intended and Unintended Targeting of Polymeric Nanocarriers: The Case of Modified Poly(glycerol adipate) Nanoparticles. *MACROMOLECULAR BIOSCIENCE*, 18: 1
128. Brandt A, Matschke J, Fehrle W, von Wenserski L, Bokemeyer C, Illerhaus G, Binder M (2019) A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells. *LEUKEMIA & LYMPHOMA*, 60: 334-340
129. Gomes de Castro MA, Wildhagen H, Sograte-Idrissi S, Hitzing C, Binder M, Trepel M, Engels N, Opazo F (2019) Differential organization of tonic and chronic B cell antigen receptors in the plasma membrane. *Nature Communications*, 10: 820
130. Harrach S, Barz V, Pap T, Pavenstädt H, Schlatter E, Edemir B, Distler J, Ciarimboli G, Bertrand J (2019) Notch Signaling Activity Determines Uptake and

- Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts. *JOURNAL OF INVESTIGATIVE DERMATOLOGY*, 139: 439-447
131. Janjetovic S, Asemissen AM, Dicker F, Binder M, Dierlamm J, Bokemeyer C, Schafhausen P (2019) Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib. *Tumori J*, epub: 300891619839473
 132. Mährle T, Akyüz N, Fuchs P, Bonzanni N, Simnica D, Germing U, Asemissen AM, Jann JC, Nolte F, Hofmann WK, Nowak D, Binder M (2019) Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide. *HAEMATOLOGICA*, 104: 1355-1364
 133. Schieferdecker A, Binder M, Weisel K, Bokemeyer C (2019) [Monoclonal Gammopathy Of Unknown Significance - A Common Incidental Finding - What is to be thought of? What has to be done?]. *DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT*, 144: 982-989
 134. Schliffke S, Carambia A, Akyüz N, Thiele B, Herkel J, Binder M (2019) T-cell repertoire profiling by next-generation sequencing reveals tissue migration dynamics of TRBV13-family clonotypes in a common experimental autoimmune encephalomyelitis mouse model. *JOURNAL OF NEUROIMMUNOLOGY*, 332: 49-56
 135. Schütte-Nütgen K, Edeling M, Mendl G, Krahn MP, Edemir B, Weide T, Kremerskothen J, Michgehl U, Pavenstädt H (2019) Getting a Notch closer to renal dysfunction: activated Notch suppresses expression of the adaptor protein Disabled-2 in tubular epithelial cells. *FASEB JOURNAL*, 33: 821-832
 136. Simnica D, Schliffke S, Schultheiß C, Bonzanni N, Fanchi LF, Akyüz N, Gösch B, Casar C, Thiele B, Schlüter J, Lohse AW, Binder M (2019) High-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias. *Frontiers in Immunology*, 10: 1897
 137. Tintelnot J, Baum N, Schultheiß C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schuetze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M (2019) Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies. *MOLECULAR CANCER THERAPEUTICS*, 18: 823-833
 138. von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani MT, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse AW, Cornelissen JJ, de Man RA, Mallet V (2019) The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. *JOURNAL OF HEPATOLOGY*, 71: 465-472
 139. Ziemens A, Sonntag SR, Wulfmeyer VC, Edemir B, Bleich M, Himmerkus N (2019) Claudin 19 Is Regulated by Extracellular Osmolality in Rat Kidney Inner Medullary Collecting Duct Cells. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*, 20: 1-10